TOPIC:
26 Aprile 2022
A Cristaudo, D Graceffa, F Pimpinelli, F Sperati, G Spoletini, C Bonifati, R Pellini, V Lora, M Pontone, O Di Bella, D Bracco, A Morrone

Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs

J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e266-e268

Key messages

  • In letteratura pochi sono i dati disponibili sull’immunogenicità e la sicurezza dei vaccini a mRNA nei pazienti affetti da psoriasi in trattamento con farmaci biologici.
  • Non è emersa una differenza statisticamente significativa nella risposta anticorpale tra i pazienti affetti da psoriasi rispetto ai controlli. In linea con la maggioranza degli autori, i farmaci biologici somministrati in monoterapia influenzano minimamente la risposta immunitaria al vaccino.

Abstract

Background
Although there is clear evidence that COVID vaccines are effective in inducing anti-Spike immunization in the majority of individuals, only limited data are available in literature on the immunogenicity and safety of mRNA vaccines in psoriatic patients treated with biologics.

Conclusions
There is ample scientific evidence to support a lack of efficacy in the antibody response of obese people to common vaccines, such as influenza, rabies, and hepatitis B. Nevertheless, in line with a recent study, our results show that the BMI does not affect the response to BNT162b2. No significant adverse events have been reported, and no flare was observed among psoriatic patients in the weeks following vaccine administration. In conclusion, our data confirm a favorable risk-benefit profile of BNT162b2 in psoriatic patients.

Tagged on:
Accedi all’abstract originale